KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Twist Bioscience (TWST) Net Margin (2017 - 2026)

Twist Bioscience has reported Net Margin over the past 10 years, most recently at 39.76% for Q1 2026.

  • Quarterly Net Margin rose 265.0% to 39.76% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 19.85% through Mar 2026, up 3514.0% year-over-year, with the annual reading at 20.62% for FY2025, 4608.0% up from the prior year.
  • Net Margin was 39.76% for Q1 2026 at Twist Bioscience, down from 29.42% in the prior quarter.
  • Over five years, Net Margin peaked at 21.22% in Q2 2025 and troughed at 126.06% in Q1 2022.
  • The 5-year median for Net Margin is 60.41% (2024), against an average of 63.39%.
  • Year-over-year, Net Margin crashed -1501bps in 2024 and then soared 12627bps in 2025.
  • A 5-year view of Net Margin shows it stood at 77.1% in 2022, then rose by 22bps to 60.15% in 2023, then skyrocketed by 41bps to 35.62% in 2024, then grew by 17bps to 29.42% in 2025, then tumbled by -35bps to 39.76% in 2026.
  • Per Business Quant, the three most recent readings for TWST's Net Margin are 39.76% (Q1 2026), 29.42% (Q4 2025), and 27.39% (Q3 2025).